Phase II Study of IL-11 (Neumega) in Von Willebrand Disease
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This study is testing the use of rhIL-11 (recombinant interleukin 11, Neumega) in individuals
with Von Willebrand disease. The purpose is to evaluate:
1. if rhIL-11 corrects VWF (Von Willebrand Factor) levels to normal
2. if rhIL-11 and DDAVP together will boost VWF levels even higher
3. the onset, peak, and duration of rhIL-11 effect
4. if rhIL-11 is safe in individuals with Von Willebrand Disease
Phase:
Phase 2
Details
Lead Sponsor:
University of Pittsburgh
Collaborators:
University of North Carolina Wyeth is now a wholly owned subsidiary of Pfizer